Vibe Bioscience Ltd (VIBE) AI Stock Analysis

• Market Cap: C$647.82K
• Dividend Yield: N/A
• Average Volume (3M): 6.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 4.48
• Revenue Growth: 32.33%
• EPS Growth: 24.01%
• Country: CA
• Employees: 110
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.07
• Shares Outstanding: 10,796,989
• 10 Day Avg. Volume: 10,465
• 30 Day Avg. Volume: 6,194
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.11
• Price to Sales (P/S): 0.04
• P/FCF Ratio: 2.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.05 ▼(-18.33% Downside)

The score is primarily held back by weak financial performance—persistent large losses, negative equity, and fragile cash generation—despite improving TTM revenue growth and stable gross margins. Technicals are moderately supportive in the near term, but valuation signals are limited by negative earnings and no dividend data.

Positive Factors

Revenue Growth Momentum

Sustained top-line growth provides a durable runway to absorb fixed costs and scale marketing and distribution. If revenue momentum persists, the business can leverage mid-30% gross margins to move toward operating leverage, reducing reliance on external capital over time.

Stable Gross Margins

Consistent mid-30% gross margins indicate resilient product economics and pricing power within its category. Stable unit economics support profitable scaling: as fixed operating expenses are spread over higher sales, margins can expand sustainably if revenue growth continues without margin erosion.

DTC + Retail Distribution and R&D Partnerships

A multi-channel model (direct-to-consumer plus retail) and ability to form licensing/research partnerships diversify revenue sources and expand reach. Structural demand for natural health solutions supports long-term volume growth and provides channels to commercialize new products without sole reliance on one distribution partner.

Negative Factors

Deeply Negative Equity

Negative equity reflects accumulated losses and materially weakens financing flexibility. Over months, this limits access to non-dilutive capital, raises refinancing risk, and increases likelihood of dilutive equity raises or restructuring, constraining strategic investments and long-term stability.

Persistent Operating Losses

Large, ongoing losses indicate the business has not yet achieved scale where revenues cover operating costs. Persistently negative margins force reliance on external funding for R&D, marketing and inventory, slowing reinvestment and risking dilution or curtailed growth if capital access tightens.

Fragile Cash Generation

Weak and volatile cash conversion undermines self-funding ability and increases dependency on financing. Limited free cash constrains sustained product development, inventory buildup, or marketing spend needed to scale, making the company vulnerable to revenue shocks and slowing durable growth prospects.

Vibe Bioscience Ltd Business Overview & Revenue Model

Company Description

Vibe Growth Corporation engages in the cultivation, production, retail, and distribution of cannabis for recreation and medicinal. The company operates five dispensaries, one distribution, and two cultivation operations, as well as sells its products through its e-commerce platform under the Vibe By California brand. It also involved in the indoor cultivation; commercial distribution and transportation; e-commerce and home delivery; and manufacturing of marijuana products. The company was formerly known as Vibe Bioscience Ltd. and changed its name to Vibe Growth Corporation in October 2020. Vibe Growth Corporation was incorporated in 2020 and is headquartered in Sacramento, California.

How the Company Makes Money

Vibe Bioscience Ltd generates revenue primarily through the sale of its cannabinoid-infused products. The company markets its products directly to consumers via online platforms and retail partnerships, capitalizing on the growing demand for natural health solutions. Additionally, VIBE may engage in strategic partnerships with healthcare providers and distributors, enhancing its market reach and driving sales. The company also potentially benefits from licensing agreements and collaborations with research institutions, enabling it to develop new products and expand its product line, which further contributes to its earnings.

Vibe Bioscience Ltd Financial Statement Overview

Summary

Revenue is growing strongly TTM (+19.0%) with steady mid-30% gross margins, but the company remains deeply unprofitable (negative EBIT/EBITDA and ~-36.8% net margin). Balance sheet risk is elevated due to deeply negative equity, and cash generation is fragile with only slightly positive operating cash flow and slightly negative free cash flow TTM.

Income Statement

TTM (Trailing-Twelve-Months) revenue is up strongly (+19.0%), showing renewed top-line momentum after multiple down years. Gross margin remains fairly steady in the mid-30% range, suggesting decent product economics. However, profitability is still weak: EBIT and EBITDA are negative and the company is still posting a sizable net loss (net margin ~-36.8% TTM), indicating the business has not yet scaled to sustainable earnings.

Balance Sheet

The balance sheet has deteriorated materially, with stockholders’ equity turning deeply negative in the most recent periods (TTM and 2024), which is a major financial risk signal and limits financing flexibility. While total debt is relatively modest in absolute terms (about 2.4M TTM), negative equity makes leverage metrics less meaningful and highlights accumulated losses. Total assets have also declined versus earlier years, reinforcing weaker underlying financial capacity.

Cash Flow

Cash generation is fragile. TTM operating cash flow is only slightly positive (~47K) and free cash flow is slightly negative, implying limited self-funding ability. Cash flow was positive in 2024 (both operating and free cash flow), but the business has shown volatility, including materially negative operating cash flow in 2022–2023. Overall, cash conversion and consistency remain key concerns despite some recent stabilization.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.59M	12.71M	14.15M	20.71M	29.29M	24.24M
Gross Profit	6.08M	4.74M	5.17M	6.49M	8.42M	8.54M
EBITDA	-2.94M	-3.91M	-8.42M	-3.63M	-1.11M	2.58M
Net Income	-6.47M	-6.54M	-11.13M	-9.45M	-4.30M	728.55K
Balance Sheet
Total Assets	16.22M	11.29M	16.28M	25.89M	32.90M	18.34M
Cash, Cash Equivalents and Short-Term Investments	1.03M	1.06M	1.17M	4.55M	9.10M	2.41M
Total Debt	2.38M	2.57M	2.89M	3.38M	2.83M	2.57M
Total Liabilities	17.87M	16.51M	15.20M	13.63M	11.50M	8.23M
Stockholders Equity	-8.64M	-5.22M	1.08M	12.26M	21.39M	10.11M
Cash Flow
Free Cash Flow	-47.45K	202.82K	-2.78M	-3.71M	-7.20M	193.36K
Operating Cash Flow	47.16K	233.74K	-2.71M	-1.97M	848.73K	724.34K
Investing Cash Flow	-94.61K	19.02K	-71.80K	-1.75M	-8.43M	362.35K
Financing Cash Flow	-338.99K	-360.37K	-595.55K	-699.14K	14.33M	-324.15K

Vibe Bioscience Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VIBE, the sentiment is Positive. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.71 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:VIBE.

Vibe Bioscience Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XBRA	49 Neutral	C$420.72K	-0.31	―	―	―	―
VIBE	47 Neutral	C$647.82K	-0.07	-201.37%	―	32.33%	24.01%
ASIA	31 Underperform	C$543.71K	-1.55	―	―	―	―